HOUSTON, October 30, 2025 — Plus Therapeutics, Inc. (Nasdaq: PSTV) reports the U.S. market introduction of its CNSide® CSF diagnostics platform and a national coverage agreement with UnitedHealthcare.
The company also presented positive results from the RESPECT-LM Ph1 clinical trial. These announcements were made along with the release of the company’s financial results for the third quarter ended September 30, 2025.
According to Marc H. Hedrick, M.D., Plus Therapeutics President and CEO, the company plans to expand its commercial team and footprint for CNSide, seek FDA clarity for its REYOBIQ™ clinical development plan, and bolster its financial position.
Highlights include receiving an additional $1.9 million advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT), regaining compliance with Nasdaq listing criteria, expanding commercial readiness for CNSide, and receiving CLIA certification for its Houston lab.
Investor Contact:
CORE IR
investor@plustherapeutics.com
Source: Plus Therapeutics
